Page 289 - Cardiac Nursing

p
p
66.
q
/29
q
q
a
65
ara
5-2
65
In
a
a
g
1 P
1 P
g
A
Pa
g
6
0:2
6
6
0:2
/09
1
1
5-2
xd
xd
66.
/09
M
M
t
a
LWBK340-c11_
LWB
LWB K34 0-c 11_ p p pp245-266.qxd 6/29/09 10:21 PM Page 265 Aptara Inc.
K34
Pa
11_
0-c
e 2
t
In
c.
24
24
/29
e 2
A
p
ara
c.
ara
C HAPTER 1 1 / Laboratory Tests Using Blood 265
size and cardiac function. Journal of the American College of Cardiology, 51. Visser, M., Bouter, L. M., McQuillan, G. M. et al. (1999). Elevated
48(11), 2192–2194. C-reactive protein levels in overweight and obese adults. Journal of the
29. Miller, W. L., Garratt, K. N., Burritt, M. F., et al. (2006). Baseline tro- American Medical Association, 282, 2131–2135.
ponin level: Key to understanding the importance of post-PCI troponin 52. Ridker, P. M., Rifai, N., Rose, L., et al. (2002). Comparison of C-reac-
7
elevation. European Heart Journal, 27, 1061–1069. tive protein and low-density lipoprotein cholesterol levels in the predic-
7
7
7
30. Kontos, M. C., Shah, R., Fritz, L. M., et al. (2004). Implication of dif- tion of first cardiovascular events. New England Journal of Medicine, 347,
ferent cardiac troponin I levels for clinical outcomes and prognosis of 1557–1565.
acute chest pain patients. Journal of the American College of Cardiology, 53. Myers, G. L., Rifai, N., Tracy, R. P., et al. (2004). CDC/AHA workshop
43, 958–965. on markers of inflammation and cardiovascular disease. Circulation, 110,
31. Roongsritong, C., Warraich, I., & Bradley, C. (2004). Common causes e545–e549.
of troponin elevations in the absence of acute myocardial infarction: In- 54. Lily, L. S. (2001). Ischemic heart disease. In J. Noble (Ed.), Textbook of
cidence and clinical significance. Chest, 125, 1877–1884. primary care medicine (pp. 545–570). St. Louis: Mosby.
32. Velmahos, G. C., Karaiskakis, M., Salim, A., et al. (2003). Normal elec- 55. Ridker, P. M. (1999). Evaluating novel cardiovascular risk factors: Can
trocardiography and serum troponin I levels preclude the presence of we better predict heart attacks? Annals of Internal Medicine, 130,
clinically significant blunt cardiac injury. Journal of Trauma: Injury, In- 933–937.
4
fection and Critical Care, 54, 45–51. 56. Homocysteine Studies Collaboration, Homocysteine and risk of is-
4
33. Dale, K. M., White, C. M., Henyan, N. N., et al. (2007). Impact of chemic heart disease and stroke. Journal of the American Medical Associ-
6
statin dosing intensity on transaminase and creatine kinase. American ation, 16, 2015–2022.
6
Journal of Medicine, 120, 706–712. 57. Bautista, L. E., Arenas, I. A., Penuela, A., et al. (2002). Total plasma ho-
34. Califf, R. M., Abdelmeguid, A. E., Kuntz, R. E., et al. (1998). My- mocysteine level and risk of cardiovascular disease: A meta-analysis of
onecrosis after revascularization procedures. Journal of the American Col- prospective cohort studies. Journal of Clinical Epidemiology, 55(9),
lege of Cardiology, 31(2), 241–251. 882–887.
35. Prasad, A., Singh, M., Lerman, A., et al. (2006). Isolated elevation in tro- 58. Cleophas, T. J., Hornstra, N., van Hoogstraten, B., et al. (2000). Ho-
ponin T after percutaneous coronary intervention is associated with mocysteine, a risk factor for coronary artery disease or not? A meta-
6
higher long-term mortality. Journal of the American College of Cardiology, analysis. American Journal of Cardiology, 86(9), 1005–1009.
6
48(9), 1765–1770. 59. Chambers, J. C., Ueland, P. M., Obeid, O. A., et al. (2000). Improved
36. Nallamothu, B. K., Chetcuti, S., Mukherjee, D., et al. (2003). Prognos- vascular endothelial function after oral B vitamins: An effect mediated
tic implication of troponin I elevation after percutaneous coronary in- through reduced concentrations of free plasma homocysteine. Circula-
tervention. American Journal of Cardiology, 91, 1272–1274. tion, 102(20), 2479–2483.
37. Klatte, K., Chaitman, B. R., Theroux, P., et al. (2001). Increased mortal- 60. de Bree, A., Verschuren, W. M., Blom, H. J., et al. (2003). Coronary
ity after coronary artery bypass graft surgery is associated with increased heart disease mortality, plasma homocysteine, and B-vitamins: a
6
levels of postoperative creatine kinase-myocardial band isoenzyme release. prospective study. Atherosclerosis, 166(2), 369–377.
6
Journal of the American College of Cardiology, 38, 1070–1077. 61. Doshi, S. N., McDowell, I. F., Moat, S. J., et al. (2002). Folic acid improves
38. Costa, M. A., Carere, R. G., Lichtenstein, S. V., et al. (2001). Incidence, endothelial function in coronary artery disease via mechanisms largely in-
predictors, and significance of abnormal cardiac enyzme rise in patients dependent of homocysteine lowering. Circulation, 105(1), 22–26.
treated with bypass surgery in the arterial revascularization therapies 62. Schnyder, G., Roffi, M., Pin, R., et al. (2001). Decreased rate of coronary
4
study (ARTS). Circulation, 104, 2689–2693. restenosis after lowering of plasma homocysteine levels. New England
4
39. Januzzi, J. L., Lewandrowski, K., MacGillivray, T. E., et al. (2002). A Journal of Medicine, 345(22), 1593–1600.
comparison of cardiac troponin T and creatine kinase-MB for patient 63. Title, L. M., Cummings, P. M., Giddens, K., et al. (2000). Effect of folic
evaluation after cardiac surgery. Journal of the American College of Cardi- acid and antioxidant vitamins on endothelial dysfunction in patients
ology, 39, 1518–1523. with coronary artery disease. Journal of the American College of Cardiol-
6
40. Kathiresan, S., Servoss, S. J., Newell, J. B., et al. (2004). Cardiac tro- ogy, 36(3), 758–765.
6
ponin T elevation after coronary artery bypass grafting is associated with 64. Wald, D. S., Bishop, L., Wald, N. J., et al. (2001). Randomized trial of
increased one-year mortality. American Journal of Cardiology, 94, folic acid supplementation and serum homocysteine levels. Archives of
879–881. Internal Medicine, 161(5), 695–700.
41. Croal, B. L., Hillis, G. S., Gibson, P. H., et al. (2006). Relationship be- 65. Rader, D. J. (2000). Inflammatory markers of coronary risk. New Eng-
tween postoperative cardiac troponin I levels and outcome of cardiac land Journal of Medicine, 343(16), 1179–1182.
4
4
surgery. Circulation, 114, 1468–1475. 66. Caslake, M. J., Packard, C. J., Suckling, K. E., et al. (2000). Lipopro-
42. Grundy, S. M., Cleeman, J. I., Merz, N. B., et al. (2004). Implications tein-associated phospholipase A(2), platelet-activating factor acetylhy-
of recent clinical trials for the National Cholesterol Education Program drolase: A potential new risk factor for coronary artery disease. Athero-
Adult Treatment Panel III Guidelines. Circulation, 110, 227–239. sclerosis, 150(2), 413–419.
43. Wallach, J. (2007). Cardiovascular diseases. In Interpretation of diagnos- 67. Packard, C. J., O’Reilly, D. S., Caslake, M. J., et al. (2000). Lipoprotein-
tic tests. Philadelphia: Lippincott Williams & Wilkins. associated phospholipase A2 as an independent predictor of coronary
44. Pearson, T. A., Mensah, G. A., Alexander, R. W., et al. (2003). Markers heart disease. West of Scotland Coronary Prevention Study Group. New
of inflammation and cardiovascular disease: Application to clinical and England Journal of Medicine, 343(16), 1148–1155.
7
7
public health practice. Circulation, 107, 499–511. 68. Blake, G. J., Dada, N., Fox, J. C., et al. (2001). A prospective evaluation
45. Ridker, P. M., Cushman, M., Stampfer, M. J., et al. (1997). Inflamma- of lipoprotein-associated phospholipase A(2) levels and the risk of future
tion, aspirin, and the risk of cardiovascular disease in apparently healthy cardiovascular events in women. American Journal of Cardiology, 38(5),
men. New England Journal of Medicine, 336, 973–979. 1302–1306.
6
6
46. Rost, N. S., Wolf, P. A., Kase, C. S., et al. (2001). Plasma concentration 69. Grantham, J. A., & Burnett, J. C. (1997). BNP: Increasing importance
of c-reactive protein and risk of ischemic stroke and transient ischemic in the pathophysiology and diagnosis of congestive heart failure. Circu-
6
6
attack. Stroke, 32, 2575–2579. lation, 96, 388–390.
47. Koenig, W., Sund, M., Frohlich, M., et al. (1999). C-reactive protein, a 70. Maisel, A. S., Krishnaswamy, P., Nowak, R. M., et al. (2002). Rapid
sensitive marker for inflammation, predicts future risk of coronary heart measurement of B-type natriuretic peptide in the emergency diagnosis of
7
disease in initially healthy middle-aged men. Circulation, 99, 237–242. heart failure. New England Journal of Medicine, 347(3), 161–167.
7
48. Kuller, L. H., Tracy, R. P., Shaten, J., et al. (1996). Relation of C-reac- 71. McCullough, P. A., Nowak, R. M., McCord, J., et al. (2002). B-type na-
tive protein and coronary heart disease in the MRFIT nested case- triuretic peptide and clinical judgment in emergency diagnosis of heart
6
6
control study. American Journal of Epidemiology, 144, 537–547. failure. Circulation, 106, 416–422.
4
4
49. Ridker, P. M., Hennekens, C. H., Buring, J. E., et al. (2000). C-reactive 72. Wieczorek, S. J., Wu, A. H., Christenson, R., et al. (2002). A rapid
protein and other markers of inflammation in the prediction of cardiovas- B-type natriuretic peptide assay accurately diagnoses left ventricular
cular disease in women. New England Journal of Medicine, 342, 836–843. dysfunction and heart failure: A multicenter evaluation. American Heart
50. Tracy, R. P., Lemaitre, R. N., Psaty, B. M., et al. (1997). Relationship of Journal, 144, 834–839.
C-reactive protein to risk of cardiovascular disease in the elderly. Arte- 73. Fonarow, G. C., Peacock, W. F., Horwich, T. B., et al. (2008). Useful-
riosclerosis, Thrombosis, and Vascular Biology, 17, 1121–1127. ness of B-type natriuretic peptide and cardiac troponin levels to predict
7
7